Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials
Long-term use of tralokinumab in adults and adolescents with moderate-to-severe AD was well-tolerated and consistent with the initial placebo-controlled treatment period, with no new safety signals identified.
Authors
- Kristian Reich (ORCID: https://orcid.org/0000-0001-5248-4332)
- Christian Bjerregård Øland (ORCID: https://orcid.org/0000-0001-8929-1761)
- Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
- Andrew Pink (ORCID: https://orcid.org/0000-0001-5151-5539)
- Amy S. Paller (ORCID: https://orcid.org/0000-0001-6187-6549)
- Norito Katoh (ORCID: https://orcid.org/0000-0002-3498-2482)
- D. Staumont‐Sallé (ORCID: https://orcid.org/0000-0002-4780-4212)
- Le Gjerum (ORCID: https://orcid.org/0000-0002-5849-1397)
- Antonio Costanzo (ORCID: https://orcid.org/0000-0001-9697-2557)
- Richard G. Langley (ORCID: https://orcid.org/0000-0003-4730-2164)
- J.F. Silvestre (ORCID: https://orcid.org/0000-0002-8532-6338)
- Andreas Wollenberg (ORCID: https://orcid.org/0000-0003-0177-8722)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Ann‐Marie Tindberg
- Andrew Blauvelt
Institutions
- Northwestern University (US)
- Dalhousie University (CA)
- St Thomas' Hospital (GB)
- Humanitas University (IT)
- Inserm (FR)
- Universität Hamburg (DE)
- Oregon Health & Science University (US)
- Université de Lille (FR)
- Manchester Academic Health Science Centre (GB)
- University Hospital Augsburg (DE)
- Northern Health and Social Care Trust (GB)
- Kyoto Prefectural University of Medicine (JP)
- Manchester University NHS Foundation Trust (GB)
- Maryland Department of Natural Resources (US)
- University Medical Center Hamburg-Eppendorf (DE)
- St. Thomas Hospital (CA)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- NIHR Manchester Biomedical Research Centre (GB)
- IRCCS Humanitas Research Hospital (IT)
- Leo Pharma (Denmark) (DK)
- Ludwig-Maximilians-Universität München (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1093/bjd/ljaf309
- Citations
- 5
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 10.02
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Celgene
- National Institute for Health and Care Research
- Galderma
- LEO Pharma
- Manchester Biomedical Research Centre
- Cilag